02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
20:59 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Bio-Path reports interim Phase II data for AML candidate

Bio-Path Holdings Inc. (NASDAQ:BPTH) reported interim data from 17 evaluable patients with previously untreated acute myelogenous leukemia (AML) who are ineligible for intensive induction therapy in a Phase II trial showing that prexigebersen (BP1001) plus...
17:35 , Nov 4, 2016 |  BC Week In Review  |  Clinical News

BP1001: Ph II started

Bio-Path began an open-label, U.S. Phase II trial to evaluate 60 mg/m2 IV BP1001 given on day 1 and every 3 days thereafter plus low-dose cytarabine twice daily for 20 consecutive days in each 28-day...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Company News

Bio-Path, Thomas Jefferson University deal

Bio-Path and the university partnered to develop Bio-Path’s DNAbilize systemic antisense immunotherapy to treat brain cancer. The DNAbilize liposomal delivery and antisense technology distributes nucleic acid drugs by IV transfusion to activate a patient’s immune...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Financial News

Bio-Path proposes direct public offering

Bio-Path Holdings Inc. (NASDAQ:BPTH), Houston, Texas   Business: Cancer   Date announced: 2016-06-29   Type: Direct public offering   To be raised: $10 million   Units: 5.9 million   Price: $1.70 (unit)   Shares outstanding...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Additional Phase I data

Data from 6 evaluable patients with advanced acute myelogenous leukemia (AML) in cohorts 7 and 8 of a dose-escalation Phase I trial showed that twice-weekly IV 60 or 90 mg/m 2 BP001 plus low-dose cytarabine...
07:00 , Oct 1, 2015 |  BC Innovations  |  Product R&D

Escaping the liver

Having addressed one of the two big problems of RNAi delivery - getting therapeutic levels of the molecules inside cells - Arrowhead Research Corp. now believes it has solved the second, with a modification to...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Phase I data

Bio-Path disclosed in its 2Q15 earnings data from 21 evaluable patients from the monotherapy portion of a dose-escalation Phase I trial showing that IV liposomal Grb-2 was well tolerated with no DLTs reported. Additionally, liposomal...
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

Liposomal Grb-2 regulatory update

FDA granted Orphan Drug designation to Liposomal Grb-2 from Bio-Path to treat acute myelogenous leukemia (AML). The liposomal antisense inhibitor of growth factor receptor-bound protein 2 (GRB2) expression is in Phase II testing for AML,...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Liposomal Grb-2: Phase II started

Bio-Path began an open-label, U.S. Phase II trial to evaluate 60 and 90 mg/m 2 IV BP-100-1.01 twice weekly in 28-day cycles in combination with cytarabine in 6 patients. Bio-Path Holdings Inc. (NASDAQ:BPTH), Houston, Texas...